ClinicalTrials.gg

Program

Niacinamide

Also written as “Nicotinamide” and “Nicotinamide (NAM)”.

Its studies are mostly in Anemia, Sickle Cell · Renal Insufficiency, Chronic, led by 3 companies.

Furthest: phase 2, since Aug 12, 20193 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EpiDestiny11 open or runningphase 1since Aug 12, 2019Aug 12, 2019Oct 30, 2028phase 1 · NCT04055818
Medice Arzneimittel Pütter GmbH & Co KG10 open or runningphase 2since Sep 10, 2010Sep 10, 2010none ahead
Metro International Biotech11 open or runningphase 1since Mar 11, 2025Mar 11, 2025Dec 2026phase 1 · NCT06882096

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2010First study: phase 2 study in Renal Insufficiency, ChronicNew to Medice Arzneimittel Pütter GmbH & Co KGMedice Arzneimittel Pütter GmbH & Co KG · NCT01200784 · 252 enrolled · Germany
  2. Aug 12, 2019EpiDestiny's first study: phase 1 study in Anemia, Sickle CellNew to EpiDestinyEpiDestiny · NCT04055818 · 20 planned · United States
  3. Mar 11, 2025Metro International Biotech's first study: phase 1 study in Healthy AdultsNew to Metro International BiotechMetro International Biotech · NCT06882096 · 32 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy AdultsMetro International Biotech · NCT06882096
  2. Oct 30, 2028Primary completion: phase 1 study in Anemia, Sickle CellEpiDestiny · NCT04055818

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06882096Healthy Adults · United States1RecruitingMetro International BiotechDec 202632
NCT04055818Anemia, Sickle Cell · United States1RecruitingEpiDestinyOct 30, 202820
NCT01200784Renal Insufficiency, Chronic · Germany2CompletedMedice Arzneimittel Pütter GmbH & Co KGJun 2011252

How it is read

Names in the registry

  • “Nicotinamide”, 2 entries
  • “Nicotinamide (NAM)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.